T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Cameco
CCJ
$43.1B
| $250M | 0.03% |
5,075,764
-1,438,736
| -22% | -$72.9M |
|
377
Moody's
MCO
$82.8B
| $249M | 0.03% |
590,440
+178,109
| +43% | +$70.9M |
|
378
Neurocrine Biosciences
NBIX
$15.9B
| $248M | 0.03% |
1,798,848
-21,948
| -1% | -$3.01M |
|
379
SS&C Technologies
SSNC
$18.8B
| $247M | 0.03% |
3,934,609
+74,353
| +2% | +$4.61M |
|
380
Domino's
DPZ
$11.7B
| $244M | 0.03% |
473,239
+28,459
| +6% | +$14.5M |
|
381
Workday
WDAY
$43.3B
| $244M | 0.03% |
1,092,952
-218,290
| -17% | -$52.6M |
|
382
BP
BP
$111B
| $243M | 0.03% |
6,740,818
+225,279
| +3% | +$8.44M |
|
383
Ascendis Pharma A/S
ASND
$16.8B
| $243M | 0.03% |
1,784,148
+2,222
| +0.1% | +$302K |
|
384
Snowflake
SNOW
$115B
| $242M | 0.03% |
1,794,685
-97,996
| -5% | -$14.5M |
|
385
lululemon athletica
LULU
$13.7B
| $242M | 0.03% |
809,309
-203,994
| -20% | -$68.2M |
|
386
Madrigal Pharmaceuticals
MDGL
$12.4B
| $241M | 0.03% |
858,765
+55,552
| +7% | +$13.2M |
|
387
Celestica
CLS
$42.8B
| $240M | 0.03% |
4,187,469
-4,516,273
| -52% | -$228M |
|
388
Noble Corp
NE
$7.04B
| $240M | 0.03% |
5,371,955
-547,791
| -9% | -$25.3M |
|
389
VF Corp
VFC
$5.73B
| $240M | 0.03% |
17,748,881
+17,306,675
| +3,914% | +$227M |
|
390
Vaxcyte
PCVX
$8.88B
| $240M | 0.03% |
3,173,167
-3,014
| -0.1% | -$205K |
|
391
Verisk Analytics
VRSK
$23.5B
| $236M | 0.03% |
876,126
+419,452
| +92% | +$103M |
|
392
Kanzhun
BZ
$7.19B
| $233M | 0.03% |
12,381,493
-432,886
| -3% | -$8.72M |
|
393
Ares Management
ARES
$32.1B
| $231M | 0.03% |
1,734,896
-2,226,947
| -56% | -$304M |
|
394
ICICI Bank
IBN
$107B
| $229M | 0.03% |
7,945,724
-675,437
| -8% | -$18.1M |
|
395
CAVA Group
CAVA
$8.09B
| $226M | 0.03% |
2,439,389
-1,031,560
| -30% | -$79.6M |
|
396
Teck Resources
TECK
$32.4B
| $224M | 0.03% |
4,667,836
+166,758
| +4% | +$8.21M |
|
397
Louisiana-Pacific
LPX
$5.15B
| $223M | 0.03% |
2,710,779
+970,530
| +56% | +$81.1M |
|
398
OneMain Financial
OMF
$7.44B
| $223M | 0.03% |
4,593,161
+35,084
| +0.8% | +$1.72M |
|
399
Royal Caribbean
RCL
$82.4B
| $222M | 0.03% |
1,394,129
-183,623
| -12% | -$26.4M |
|
400
Huntington Ingalls Industries
HII
$12.9B
| $222M | 0.03% |
901,038
-164,074
| -15% | -$42.6M |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.